Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)

NCT04547140 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

57

Enrollment

INDUSTRY

Sponsor class

Stopped Study Stopped for Futility

Conditions

COVID-19

Interventions

BIOLOGICAL: Liquid Alpha1-Proteinase Inhibitor (Human)
DRUG: Placebo
DRUG: Standard Medical Treatment

Sponsor

Grifols Therapeutics LLC